Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

Using FDA regulatory data, we compared GLP-1 RAs, GLP-1/GIP dual agonists and non-GLP-1 weight loss agents, finding the greatest weight reductions with tirzepatide and liraglutide. While efficacy outcomes were favourable, safety signals were limited by small sample sizes. Expanded real-world evidence is needed to better characterize long-term safety.